Pharmala Biotech Holdings (XCNQ:MDMA) Days Sales Outstanding : 19.35 (As of Nov. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings Days Sales Outstanding?

Pharmala Biotech Holdings's average Accounts Receivable for the three months ended in Nov. 2023 was C$0.16 Mil. Pharmala Biotech Holdings's Revenue for the three months ended in Nov. 2023 was C$0.75 Mil. Hence, Pharmala Biotech Holdings's Days Sales Outstanding for the three months ended in Nov. 2023 was 19.35.

The historical rank and industry rank for Pharmala Biotech Holdings's Days Sales Outstanding or its related term are showing as below:

XCNQ:MDMA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 32.19 Med: 91.21 Max: 107.63
Current: 32.19

During the past 3 years, Pharmala Biotech Holdings's highest Days Sales Outstanding was 107.63. The lowest was 32.19. And the median was 91.21.

XCNQ:MDMA's Days Sales Outstanding is ranked better than
83.74% of 892 companies
in the Biotechnology industry
Industry Median: 72.245 vs XCNQ:MDMA: 32.19

Pharmala Biotech Holdings's Days Sales Outstanding increased from Nov. 2022 (0.00) to Nov. 2023 (19.35).

Pharmala Biotech Holdings Days Sales Outstanding Historical Data

The historical data trend for Pharmala Biotech Holdings's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Days Sales Outstanding Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Days Sales Outstanding

107.63

74.78

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Days Sales Outstanding	Get a 7-Day Free Trial						-	65.74	-	40.53	19.35

Competitive Comparison of Pharmala Biotech Holdings's Days Sales Outstanding

For the Biotechnology subindustry, Pharmala Biotech Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Days Sales Outstanding falls into.

Pharmala Biotech Holdings Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Pharmala Biotech Holdings's Days Sales Outstanding for the fiscal year that ended in Aug. 2023 is calculated as

	Days Sales Outstanding (A: Aug. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Aug. 2022 )	+	Accounts Receivable (A: Aug. 2023 ))	/	count )	/	Revenue (A: Aug. 2023 )	*	Days in Period
=	( (0.023	+	0.195)	/	2 )	/	0.532	*	365
=	0.109					/	0.532	*	365
=	74.78

Pharmala Biotech Holdings's Days Sales Outstanding for the quarter that ended in Nov. 2023 is calculated as:

	Days Sales Outstanding (Q: Nov. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Aug. 2023 )	+	Accounts Receivable (A: Nov. 2023 ))	/	count )	/	Revenue (A: Nov. 2023 )	*	Days in Period
=	( (0.195	+	0.124)	/	2 )	/	0.752	*	365 / 4
=	0.1595					/	0.752	*	365 / 4
=	19.35

Pharmala Biotech Holdings (XCNQ:MDMA) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Pharmala Biotech Holdings Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings (XCNQ:MDMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

PMBHF:USA

Address

82 Richmond Street East, Toranto, ON, CAN, M5C 1P1

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.

Pharmala Biotech Holdings (XCNQ:MDMA) Headlines

No Headlines